Vertex Pharmaceuticals
VRTX
NZ$738.06
Share price
-1.68%
Change (1 day)
-3.87%
Change (1 year)
Categories
Market capitalization of Vertex Pharmaceuticals (VRTX)
Market cap: NZ$189.53 Billion
As of June 2025 Vertex Pharmaceuticals has a market cap of NZ$189.53 Billion. This makes Vertex Pharmaceuticals the world's 159th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of Vertex Pharmaceuticals from 1996 to 2025
End of year Market Cap
| Year | Marketcap | Change |
|---|---|---|
| 2025 | NZ$189.53 B | 1.54% |
| 2024 | NZ$186.65 B | 12.58% |
| 2023 | NZ$165.79 B | 42% |
| 2022 | NZ$116.75 B | 42.69% |
| 2021 | NZ$81.82 B | -3.94% |
| 2020 | NZ$85.17 B | 1.16% |
| 2019 | NZ$84.19 B | 33.57% |
| 2018 | NZ$63.03 B | 18.13% |
| 2017 | NZ$53.36 B | 102.3% |
| 2016 | NZ$26.37 B | -41.75% |
| 2015 | NZ$45.28 B | 23.53% |
| 2014 | NZ$36.65 B | 73.42% |
| 2013 | NZ$21.13 B | 91% |
| 2012 | NZ$11.06 B | 24.7% |
| 2011 | NZ$8.87 B | -3.96% |
| 2010 | NZ$9.24 B | -21.66% |
| 2009 | NZ$11.79 B | 59.21% |
| 2008 | NZ$7.40 B | 83.87% |
| 2007 | NZ$4.02 B | -39.85% |
| 2006 | NZ$6.69 B | 53% |
| 2005 | NZ$4.37 B | 265.96% |
| 2004 | NZ$1.19 B | -3.7% |
| 2003 | NZ$1.24 B | -46.28% |
| 2002 | NZ$2.31 B | -47.97% |
| 2001 | NZ$4.44 B | -53.79% |
| 2000 | NZ$9.61 B | 459.13% |
| 1999 | NZ$1.72 B | 20.16% |
| 1998 | NZ$1.43 B | -0.17% |
| 1997 | NZ$1.43 B | 19.31% |
| 1996 | NZ$1.20 B |
End of Day market cap according to different sources
On Jun 19th, 2025 the market cap of Vertex Pharmaceuticals was reported to be:
NZ$192.76 Billion
NZ$192.76 Billion
Market capitalization for similar companies or competitors
| Name | Marketcap | Market cap differencediff. | Country |
|---|---|---|---|
 Gilead Sciences GILD | NZ$225.94 B | 19.21% | 🇺🇸 USA |
 AbbVie ABBV | NZ$547.95 B | 189.11% | 🇺🇸 USA |
 Merck MRK | NZ$332.34 B | 75.35% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | NZ$159.64 B | -15.77% | 🇺🇸 USA |
 Johnson & Johnson JNJ | NZ$603.35 B | 218.34% | 🇺🇸 USA |
 Enanta Pharmaceuticals
ENTA | NZ$0.25 B | -99.86% | 🇺🇸 USA |